Investigation of adverse effects following COVID-19 immunization: A comparison of six vaccines in Pakistan
Abstract
Aim: This survey was created to find out the prevalence of immunized people and its objectives include evaluating how the general public responded to the six different COVID-19 vaccination and the range and severity of six COVID-19 vaccine adverse effects that participants self-reported. Methodology: A cross-sectional survey using questionnaires was carried out. The development and proper validation of a self-administered questionnaire were completed. SPSS version 23.0 was used to analyze data. For statistical evaluation, descriptive analysis was used to determine demographic frequency and percentage, other questions, and adverse effects. Analysis of associations between study variables was done using chi-square tests. Each participant gave verbal consent before the collection of data. The participants’ confidentiality was protected. Results: A total of 493 participants were enrolled in the study, with 42.6% of them falling between the age range of 21 to 30 years. A total of 493 people had acquired vaccinations; of these, 25.96% had obtained Sinopharm, 22.31% had received Cansino Pakvac, 16.63% had acquired Pfizer, 12.57% had given Sinovac, 11.96% had obtained Moderna, and 10.54% had received AstraZeneca. These vaccines’ most significant adverse effects included injection site pain, fever, headache, weariness, myalgia, joint pain, and chills. Conclusion: Even though after receiving the first dose of the vaccination, over 55% of those who received it reported musculoskeletal side effects, such as muscle aches and fatigue, we found that participants generally accepted the vaccination. After obtaining the second vaccine shot, it was observed that participants did not have as many adverse effects.
References
[1] Al-Hindy HA, Mazin J, Hashim HO. BCG Vaccine in preventing COVID-19 epidemic had to be reviewed: correlation does not imply causation. Australian Journal of Basic and Applied Sciences. 2020; 14(11): 58-63. doi: 10.22587/ajbas.2020.14.11.6
[2] Alzarea AI, Khan YH, Alatawi AD, et al. Surveillance of Post-Vaccination Side Effects of COVID-19 Vaccines among Saudi Population: A Real-World Estimation of Safety Profile. Vaccines. 2022; 10(6): 924. doi: 10.3390/vaccines10060924
[3] WHO (World Health Organization). Naming the coronavirus disease (COVID-19) and the virus that causes it. Brazilian Journal of Implantology and Health Sciences. 2020; 2(3).
[4] Chan WF, Yuan S, Kok K, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster. Lancet. 2020; 395: 514–523. doi: 10.1016/S0140-6736(20)30154-9
[5] Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. New England Journal of Medicine. 2020; 382(8): 727-733. doi: 10.1056/nejmoa2001017
[6] Li H, Liu Z, Ge J. Scientific research progress of COVID‐19/SARS‐CoV‐2 in the first five months. Journal of Cellular and Molecular Medicine. 2020; 24(12): 6558-6570. doi: 10.1111/jcmm.15364
[7] Haidere MF, Ratan ZA, Nowroz S, et al. COVID-19 Vaccine: Critical Questions with Complicated Answers. Biomolecules & Therapeutics. 2021; 29(1): 1-10. doi: 10.4062/biomolther.2020.178
[8] Trivedi A, Sharma S, Ashtey B. Investigational treatments for COVID-19. The Pharmaceutical Journal. 2020; 304(7938). doi: 10.1211/PJ.2020.20208051
[9] Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New England Journal of Medicine. 2020; 383(27): 2603-2615. doi: 10.1056/nejmoa2034577
[10] Soiza RL, Scicluna C, Thomson EC. Efficacy and safety of COVID-19 vaccines in older people. Age and Ageing. 2020; 50(2): 279-283. doi: 10.1093/ageing/afaa274
[11] Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England journal of medicine. 2021; 384(5): 403-416. doi: 10.1056/NEJMoa2305478
[12] Dolgin E. COVID-19 vaccines poised for launch, but impact on pandemic unclear. Nature Biotechnology. Published online November 25, 2020. doi: 10.1038/d41587-020-00022-y
[13] Walsh EE, Frenck RW, Falsey AR, et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. New England Journal of Medicine. 2020; 383(25): 2439-2450. doi: 10.1056/nejmoa2027906
[14] Siddique S, Ahmed S. COVID-19 Vaccines in Pakistan: Efficacy, Adverse Effects and Availability. Journal of Islamabad Medical & Dental College. 2021; 10(2): 125-130. doi: 10.35787/jimdc.v10i2.723
[15] WHO. The Sinopharm COVID-19 vaccine: What you need to know 2021. Available online: https://www.who.int/news-room/feature-stories/detail/the-sinopharm-covid-19-vaccine-what-you-need-to-know (accessed on 9 March 2024).
[16] Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomized, controlled, phase 2/3 trial. Lancet. 2020; 396(10267). doi: 10.1016/S0140-6736(20)32466-1
[17] Desalegn M, Garoma G, Tamrat H, et al. The prevalence of AstraZeneca COVID-19 vaccine side effects among Nigist Eleni Mohammed memorial comprehensive specialized hospital health workers. Cross sectional survey. PLOS ONE. 2022; 17(6): e0265140. doi: 10.1371/journal.pone.0265140
[18] Sufyan M, Sana A, Asif L, et al. Assessment of knowledge, attitude, and practice of community pharmacists toward chronic obstructive pulmonary disease. Discovery. 2024; 60(334): 1-13. doi: 10.54905/disssi.v60i334.e10d1416
[19] Shazma M, Saba N, Ayesha S, Kashif I. Knowledge, attitude, anxiety and preventive behaviors regarding Covid-19 affliction among healthcare workers in Pakistan. Pharmaceutical Drug Regulatory Affair Journal. 2024; 7(1): 000158.
[20] Chileshe M, Mupeta G, Kasanga M, et al. Prevalence of Adverse Events Post-COVID-19 Vaccination amongst the Adult Zambian Population. Journal of Biomedical Research & Environmental Sciences. 2021; 2(12): 1315-1321. doi: 10.37871/jbres1389
[21] Selvaraj P, Muthu S, Jeyaraman N, et al. Incidence and severity of SARS-CoV-2 virus post COVID-19 vaccination: A cross-sectional study in India. Clinical Epidemiology and Global Health. 2022; 14: 100983. doi: 10.1016/j.cegh.2022.100983
[22] Camacho Moll ME, Salinas Martínez AM, Tovar Cisneros B, et al. Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population. Frontiers in Public Health. 2022; 10. doi: 10.3389/fpubh.2022.834744
[23] Amita S. Acceptance and adverse effects following COVID-19 vaccination among the health care workers at a health care center in the most backward district of India. Journal of Family Medicine and Primary Care. 2022; 11(6): 3224-3229. doi: 10.4103/jfmpc.jfmpc_2370_21
[24] Mohsin M, Mahmud S, Mian AU, et al. Side Effects of COVID-19 Vaccines and Perceptions about COVID-19 and Its Vaccines in Bangladesh: A Cross-Sectional Study. Vaccine. 2022; X12(100207). doi: 10.j.jvacx.2022.100207
Copyright (c) 2024 Ayesha Sana, Saba Noor, Kashif Iqbal, Shazma Maryam, Najam-us- Sahar, Muhammad Sufyan
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors contributing to this journal agree to publish their articles under the Creative Commons Attribution 4.0 International License, allowing third parties to share their work (copy, distribute, transmit) and to adapt it for any purpose, even commercially, under the condition that the authors are given credit. With this license, authors hold the copyright.
